Long-COVID, neurological and cardiovascular disorders
DOI:
https://doi.org/10.12775/JEHS.2023.13.03.048Keywords
COVID-19, Long-COVID, clinical signs, nervous and cardiovascular systems, cognitive impairment, consequences, health; environmentAbstract
Introduction. After the disease COVID-19 caused by the SARS-CoV-2 virus, many people recover completely, but others have symptoms that persist for weeks, months or even years after the illness, with the number of patients who are worried about the signs of Long-COVID constantly growing.
The aim. Study of the features of the epidemiological and clinical course, pathophysiological mechanisms of long-COVID development, based on the study and analysis of modern scientific data and the establishment of causal relationships of damage to the nervous and cardiovascular systems.
Materials and methods. The electronic databases Scopus, PubMed, Web of Science, using modern technologies (Obsidian), key terms and words related to Long COVID, distant neurological and cardio-vascular complications have been studied and analyzed.
Conclusions. "Long COVID" is conceptualized as a multiorgan disorder with a wide range of clinical signs that may indicate primarily damage to the nervous and cardiovascular systems. Central or peripheral nervous system lesions occur in more than one-third of patients. Cardiovascular complications, including stroke, are the predominant causes of death of people with "long COVID" (40 %). The most frequent neurological signs of "Long COVID" (>70 %) are fatigue, headache, sleep disorders, emotional disorders and sensorimotor disorders. The processes of neuroinflammatory and oxidative stress predominate in the spread of neurological consequences of "Long COVID".
References
Rossman H, Shilo S, Meir T, et al. COVID-19 dynamics after a national immunization program in Israel. Nat Med 2021; 27: 1055–1061.
Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med 2021; 27: 1370–1378.
Podavalenko, A., Malysh, N., Zadorozhna, V., Chemych, M., Birukova, S., & Chorna, I. (2022). The current epidemic situation of infections with airborne transmission of viral etiology in Ukraine. Bangladesh Journal of Medical Science, 21(3), 610–619. https://doi.org/10.3329/bjms.v21i3.59575
Mykola D. Chemych, Dmytro S. Sosnovenko, Zoryana V. Kobliuk, & Nataliia V. Skrypka. (2022). The impact of the pandemic caused by covid-19 on the epidemiological state of HIV infection in Ukraine. Eastern Ukrainian Medical Journal, 10(2), 173-181. https://doi.org/10.21272/eumj.2022;10(2):173-181
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615.
Centers for Disease Control Prevention (CDC). Post-COVID conditions: information for healthcare providers, 2021, https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
World Health Organization (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021, 2021, https://www.who.int/docs/default-source/coronaviruse/corrigendum-2021.1-post-covid-19-clinical-case-definition-2021-10-06-corr-2021-10-06-en.pdf?sfvrsn=1ebb697c_5
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615.
25. Ruggeri RM, Campennì A, Deandreis D, et al. SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives. Expert Rev Clin Immunol 2021; 17: 737–759.
Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8: 416–427.
Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol 2021; 28: 3517–3529.
Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603–605.
Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220–232.
Jarrahi A, Ahluwalia M, Khodadadi H, et al. Neurological consequences of COVID-19: what have we learned and where do we go from here? J Neuroinflammation 2020; 17: 286.
Zhang X, Wang F, Shen Y, et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open 2021; 4: e2127403.
Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019.
Pilotto A, Cristillo V, Cotti Piccinelli S, et al. Long-term neurological manifestations of COVID-19: prevalence and predictive factors. Neurol Sci 2021; 42: 4903–4907.
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144.
Long-term cardiovascular outcomes of COVID-19 [Electronic resource] / Yan Xie [et al.] // Nature medicine. – 2022. – Vol. 28, No. 3. – pp. 583–590. Access mode: https://doi.org/10.1038/s41591-022-01689-3.
Long-term mortality following SARS-CoV-2 infection: A national cohort study from Estonia [Electronic resource] / Anneli Uusküla [et al.] // The lancet regional health - europe. – 2022. - P. 100394. Access mode: https://doi.org/10.1016/j.lanepe.2022.100394.
Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med 2021; 27: 28–33.
Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020; 77: 1018–1027.
Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020; 181: 894–904.e899.
Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med 2020; 383: 989–992.
Bulfamante G, Bocci T, Falleni M, et al. Brainstem neuropathology in two cases of COVID-19: SARS-CoV-2 trafficking between brain and lung. J Neurol 2021; 268: 4486–4491.
Understanding the heart-brain axis response in COVID-19 patients: a suggestive perspective for therapeutic development [Electronic resource] / Vincenzo Lionetti [et al.] // Pharmacological research. – 2021. - Vol. 168. – Access mode: https://doi.org/10.1016/j.phrs.2021.105581.
Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med 2020; 383: 989–992.
Lewis A, Frontera J, Placantonakis DG, et al. Cerebrospinal fluid in COVID-19: a systematic review of the literature. J Neurol Sci 2021; 421: 117316.
Eshak N, Abdelnabi M, Ball S, et al. Dysautonomia: an overlooked neurological manifestation in a critically ill COVID-19 patient. Am J Med Sci 2020; 360: 427–429.
Aoyagi Y, Ohashi M, Funahashi R, et al. Oropharyngeal dysphagia and aspiration pneumonia following coronavirus disease 2019: a case report. Dysphagia 2020; 35: 545–548.
Doykov I, Hällqvist J, Gilmour KC, et al. ‘The long tail of Covid-19’ – The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res 2020; 99: 1349.
Visvabharathy L, Hanson B, Orban Z, et al. Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. medRxiv, 2021, https://www.medrxiv.org/content/10.1101/2021.08.08.21261763v1.full
Kanberg N, Simrén J, Edén A, et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. Ebiomedicine 2021; 70: 103512.
Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature 2021; 595: 565–571.
Byambasuren O, Cardona M, Bell K, et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. J Ass Med Microb Infect Dis Canada 2020; 5: 223–234.
He J, Guo Y, Mao R, et al. Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol 2021; 93: 820–830.
Berlit P, Bösel J, Gahn G, et al. ‘Neurological manifestations of COVID-19’ – guideline of the German society of neurology. Neurol Res Pract 2020; 2: 51.
Ding H, Yin S, Cheng Y, et al. Neurologic manifestations of nonhospitalized patients with COVID-19 in Wuhan, China. Medcomm 2020; 1: 253–256.
Stam HJ, Stucki G, Bickenbach J. Covid-19 and post intensive care syndrome: a call for action. J Rehabil Med 2020; 52: jrm00044.
Rawal G, Yadav S, Kumar R. Post-intensive care syndrome: an overview. J Transl Inter Med 2017; 5: 90.
Iqbal FM, Lam K, Sounderajah V, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine 2021; 36: 100899.
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021; 27: 626–631.
Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021; 27: 258–263.
Vahidy FS, Pan AP, Ahnstedt H, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area. PLoS ONE 2021; 16: e0245556.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Oleksandr Saienko, Mykola Chemych, Vladyslav Svitailo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 319
Number of citations: 0
